Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole Willemsen-Seegers

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Structural Biology: X|July 11, 2020
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158Yvonne Grobben, Joost C M Uitdehaag, Nicole Willemsen-Seegers, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 19, 2020
High-Throughput Fluorescence-Based Activity Assay for Arginase-1Yvonne Grobben, Nicole Willemsen-Seegers, Joost C M Uitdehaag, et al.
Journal of Molecular Biology|January 4, 2017
Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon ResonanceNicole Willemsen-Seegers, Joost C M Uitdehaag, Martine B W Prinsen, et al.
Angewandte Chemie (International Ed. in English)|April 12, 2017
Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-SpineHeike K Wentsch, Niklas M Walter, Mike Bührmann, et al.
Journal of Medicinal Chemistry|August 24, 2017
Design, Synthesis, and Biological Evaluation of Novel Type I<sup>1</sup>/<sub>2</sub> p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-SpineNiklas M Walter, Heike K Wentsch, Mike Bührmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2021
Mapping Arginase Expression with <sup>18</sup>F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino AcidsGonçalo S Clemente, Inês F Antunes, Santosh Kurhade, et al.
Molecular Cancer Therapeutics|November 2, 2018
Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Joost C M Uitdehaag, Jeffrey J Kooijman, Jeroen A D M de Roos, et al.
Oncotarget|April 19, 2017
Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell linesMarion A A Libouban, Jeroen A D M de Roos, Joost C M Uitdehaag, et al.
Journal of Molecular Biology|May 26, 2017
Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative ActivityJoost C M Uitdehaag, Jos de Man, Nicole Willemsen-Seegers, et al.
Molecular Cancer Therapeutics|September 3, 2016
Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 InhibitorsJoost C M Uitdehaag, Jeroen A D M de Roos, Martine B W Prinsen, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Structural Biology: X|July 11, 2020
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158Yvonne Grobben, Joost C M Uitdehaag, Nicole Willemsen-Seegers, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 19, 2020
High-Throughput Fluorescence-Based Activity Assay for Arginase-1Yvonne Grobben, Nicole Willemsen-Seegers, Joost C M Uitdehaag, et al.
Journal of Molecular Biology|January 4, 2017
Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon ResonanceNicole Willemsen-Seegers, Joost C M Uitdehaag, Martine B W Prinsen, et al.
Angewandte Chemie (International Ed. in English)|April 12, 2017
Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-SpineHeike K Wentsch, Niklas M Walter, Mike Bührmann, et al.
Journal of Medicinal Chemistry|August 24, 2017
Design, Synthesis, and Biological Evaluation of Novel Type I<sup>1</sup>/<sub>2</sub> p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-SpineNiklas M Walter, Heike K Wentsch, Mike Bührmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2021
Mapping Arginase Expression with <sup>18</sup>F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino AcidsGonçalo S Clemente, Inês F Antunes, Santosh Kurhade, et al.
Molecular Cancer Therapeutics|November 2, 2018
Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Joost C M Uitdehaag, Jeffrey J Kooijman, Jeroen A D M de Roos, et al.
Oncotarget|April 19, 2017
Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell linesMarion A A Libouban, Jeroen A D M de Roos, Joost C M Uitdehaag, et al.
Journal of Molecular Biology|May 26, 2017
Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative ActivityJoost C M Uitdehaag, Jos de Man, Nicole Willemsen-Seegers, et al.
Molecular Cancer Therapeutics|September 3, 2016
Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 InhibitorsJoost C M Uitdehaag, Jeroen A D M de Roos, Martine B W Prinsen, et al.
Pageof 2